MedPath

Shanghai Renji Hospital,Shanghai Jiaotong University,School of Medicine

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

512

Active:12
Completed:91

Trial Phases

6 Phases

Early Phase 1:8
Phase 1:17
Phase 2:54
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (315 trials with phase data)• Click on a phase to view related trials

Not Applicable
178 (56.5%)
Phase 2
54 (17.1%)
Phase 4
41 (13.0%)
Phase 1
17 (5.4%)
Phase 3
17 (5.4%)
Early Phase 1
8 (2.5%)

EEG-TMS Intervening Against Postoperative Delirium

Not Applicable
Not yet recruiting
Conditions
Postoperative Delirium
First Posted Date
2025-08-03
Last Posted Date
2025-08-03
Lead Sponsor
RenJi Hospital
Target Recruit Count
98
Registration Number
NCT07100197
Locations
🇨🇳

Renji hosipical, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Independent Effects of Visceral Adipose Volume and Density on Patient Survival in Peritoneal Dialysis

Completed
Conditions
Uremia
End Stage Renal Disease on Dialysis
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
RenJi Hospital
Target Recruit Count
358
Registration Number
NCT07086430

Etomidate Combined With Propofol Versus Propofol for Sedation in High-Altitude Patients During Gastroscopy: a Randomized Multicenter Clinical Trial

Not Applicable
Not yet recruiting
Conditions
Gastrointestinal Endoscopy
Interventions
First Posted Date
2025-07-22
Last Posted Date
2025-07-22
Lead Sponsor
RenJi Hospital
Target Recruit Count
732
Registration Number
NCT07079176

REST4-AAA Registry

Not yet recruiting
Conditions
Abdominal Aortic Aneurysm
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
RenJi Hospital
Target Recruit Count
70
Registration Number
NCT07056491
Locations
🇨🇳

Ren Ji Hospital Afflited to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China

The Effectiveness of a TTM-based Multidisciplinary Collaboration on Cardiac Rehabilitation Outcomes in Patients With AMI

Not Applicable
Completed
Conditions
Acute Myocardial Infarction
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
RenJi Hospital
Target Recruit Count
86
Registration Number
NCT07045220
Locations
🇨🇳

Renji Hospital, Shanghai, China

🇨🇳

Renji Hospital, Shanghai, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 102
  • Next

News

Lenvatinib-Tislelizumab Combo Shows Promising 93% Response Rate in Rare Hereditary Kidney Cancer

Phase 2 study demonstrates remarkable 93.3% objective response rate for lenvatinib plus tislelizumab in treating fumarate hydratase-deficient renal cell carcinoma, with 20% achieving complete response.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.